Tryptophan-2,3-Dioxygenase (TDO) deficiency is associated with subclinical neuroprotection in a mouse model of multiple sclerosis.

MLA

Lanz, Tobias V., et al. “Tryptophan-2,3-Dioxygenase (TDO) Deficiency Is Associated with Subclinical Neuroprotection in a Mouse Model of Multiple Sclerosis.” Scientific Reports, vol. 7, Jan. 2017, p. 41271. EBSCOhost, https://doi.org/10.1038/srep41271.

APA

Lanz, T. V., Williams, S. K., Stojic, A., Iwantscheff, S., Sonner, J. K., Grabitz, C., Becker, S., Böhler, L.-I., Mohapatra, S. R., Sahm, F., Küblbeck, G., Nakamura, T., Funakoshi, H., Opitz, C. A., Wick, W., Diem, R., & Platten, M. (2017). Tryptophan-2,3-Dioxygenase (TDO) deficiency is associated with subclinical neuroprotection in a mouse model of multiple sclerosis. Scientific Reports, 7, 41271. https://doi.org/10.1038/srep41271

Chicago

Lanz, Tobias V, Sarah K Williams, Aleksandar Stojic, Simeon Iwantscheff, Jana K Sonner, Carl Grabitz, Simon Becker, et al. 2017. “Tryptophan-2,3-Dioxygenase (TDO) Deficiency Is Associated with Subclinical Neuroprotection in a Mouse Model of Multiple Sclerosis.” Scientific Reports 7 (January): 41271. doi:10.1038/srep41271.